Citations

Showing 10 of 108152 citations.

Effect of Advanced Glycation End Products on Cognition in Older Adults with Type 2 Diabetes: Results from a Pilot Clinical Trial
Lotan, Roni , Ganmore, Ithamar , Livny, Abigail , Itzhaki, Nofar, Waserman, Mark, Zacharia, Moran, Moshier, Erin , Uribarri, Jaime , Beisswenger, Paul J. , Cai, Weijing, Troen, Aron M. , Beeri, Michal Schnaider , Uribarri, Jaime , Waserman, Mark, Shelly, Shahar

Mayo Clinic

Journal of Alzheimer's Disease | July 7, 2021 | Volume: 82 | Issue: 4 | Pages: 1785-1795

10.3233/jad-210131 | PMID 34250935 Get It

Background: Dietary advanced glycation end-products (AGEs) are linked to cognitive decline. However, clinical trials have not tested the effect of AGEs on cognition in older adults. Objective: The aim of the current pilot trial was to examine the feasibility of an intervention to reduce dietary AGEs on cognition and on cerebral blood flow (CBF). Methods: The design is a pilot randomized controlled trial of dietary AGEs reduction in older adults with type 2 diabetes. Seventy-five participants were randomized to two arms. The control arm received standard of care (SOC) guidelines for good glycemic control; the intervention arm, in addition to SOC guidelines, were instructed to reduce their dietary AGEs intake. Global cognition and CBF were assessed at baseline and after 6 months of intervention. Results: At baseline, we found a reverse association between AGEs and cognitive functioning, possibly reflecting the long-term toxicity of AGEs on the brain. There was a significant improvement in global cognition at 6 months in both the intervention and SOC groups which was more prominent in participants with mild cognitive impairment. We also found that at baseline, higher AGEs were associated with increased CBF in the left inferior parietal cortex; however, 6 months of the AGEs lowering intervention did not affect CBF levels, despite lowering AGEs exposure in blood. Conclusion: The current pilot trial focused on the feasibility and methodology of intervening through diet to reduce AGEs in older adults with type 2 diabetes. Our results suggest that participants with mild cognitive impairment may benefit from an intensive dietary intervention.
Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome
Bierle, Dennis M. , Aakre, Christopher A. , Grach, Stephanie L. , Salonen, Bradley R. , Croghan, Ivana T. , Ganesh, Ravindra , Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L

Mayo Clinic

Journal of Primary Care & Community Health | July 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211030826 | PMID 34231404 Get It

Objective To develop and implement criteria for description of post COVID syndrome based on analysis of patients presenting for evaluation at Mayo Clinic Rochester between November 2019 and August 2020. Methods A total of 465 patients with a history of testing positive for COVID-19 were identified and their medical records reviewed. After a thorough review, utilizing the DELPHI methods by an expert panel, 42 (9%) cases were identified with persistent central sensitization (CS) symptoms persisting after the resolution of acute COVID-19, herein referred to as Post COVID syndrome (PoCoS). In this report we describe the baseline characteristics of these PoCoS patients. Results Among these 42 PoCoS patients, the mean age was 46.2 years (median age was 46.5 years). Pain (90%), fatigue (74%), dyspnea (43%), and orthostatic intolerance (38%) were the most common symptoms. The characteristics of an initial 14 patients were utilized for the development of clinical criteria via a modified Delphi Method by a panel of experts in central sensitization disorders. These criteria were subsequently applied in the identification of 28 additional cases of suspected PoCoS. A 2-reviewer system was used to analyze agreement with using the criteria, with all 28 cases determined to be either probable or possible cases by the reviewers. Inter-reviewer agreement using these proposed defining criteria was high with a Cohen’s alpha of .88. Conclusions Here we present what we believe to be the first definitional criteria for Post COVID syndrome. These may be useful in clinical phenotyping of these patients for targeted treatment and future research.
PROMIS Scales for Assessment of Persistent Post-COVID Symptoms: A Cross Sectional Study
Ganesh, Ravindra , Ghosh, Aditya , Nyman, M. , Croghan, Ivana T. , Grach, Stephanie L. , Anstine, Christopher V. , Salonen, Bradley R. , Ghosh, Aditya K, Nyman, Mark A, Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L , Ghosh, Aditya K

Mayo Clinic

Journal of Primary Care & Community Health | July 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211030413 | PMID 34231395 Get It

Objective Persistent post-COVID symptoms are estimated to occur in up to 10% of patients who have had COVID-19. These lingering symptoms may persist for weeks to months after resolution of the acute illness. This study aimed to add insight into our understanding of certain post-acute conditions and clinical findings. The primary purpose was to determine the persistent post COVID impairments prevalence and characteristics by collecting post COVID illness data utilizing Patient-Reported Outcomes Measurement Information System (PROMIS ® ). The resulting measures were used to assess surveyed patients physical, mental, and social health status. Methods A cross-sectional study and 6-months Mayo Clinic COVID recovered registry data were used to evaluate continuing symptoms severity among the 817 positive tested patients surveyed between March and September 2020. The resulting PROMIS ® data set was used to analyze patients post 30 days health status. The e-mailed questionnaires focused on fatigue, sleep, ability to participate in social roles, physical function, and pain. Results The large sample size (n = 817) represented post hospitalized and other managed outpatients. Persistent post COVID impairments prevalence and characteristics were determined to be demographically young (44 years), white (87%), and female (61%). Dysfunction as measured by the PROMIS ® scales in patients recovered from acute COVID-19 was reported as significant in the following domains: ability to participate in social roles (43.2%), pain (17.8%), and fatigue (16.2%). Conclusion Patient response on the PROMIS ® scales was similar to that seen in multiple other studies which used patient reported symptoms. As a result of this experience, we recommend utilizing standardized scales such as the PROMIS ® to obtain comparable data across the patients’ clinical course and define the disease trajectory. This would further allow for effective comparison of data across studies to better define the disease process, risk factors, and assess the impact of future treatments.
Per-pass analysis of recanalization and good neurological outcome in thrombectomy for stroke: Systematic review and meta-analysis
Larco, Jorge Arturo , Abbasi, Mehdi , Liu, Yang , Kadirvel, Ramanathan , Brinjikji, Waleed , Arturo Larco, Jorge L , Madhani, Sarosh Irfan , Shahid, Adnan Hussain , Kadirvel, Ram , Brinjikji, Waleed , Savastano, Luis E., Liu, Yang , Savastano, Luis

Mayo Clinic

Interventional Neuroradiology | July 7, 2021 | Volume: 28 | Issue: 3 | Pages: 358-363

10.1177/15910199211028342 | PMID 34229523 Get It

Background and aim First pass effect (FPE) is defined as achieving a complete recanalization with a single thrombectomy device pass. Although clinically desired, FPE is reached in less than 30% of thrombectomy procedures. Multiple device passes are often necessary to achieve successful or complete recanalization. We performed a systematic review and meta-analysis to determine the recanalization rate after each pass of mechanical thrombectomy and its association with good neurological outcome. Methods A literature search was performed for studies reporting the number of device passes required for either successful (mTICI 2b or higher) or complete (mTICI 2c or higher) recanalization. Using random-effect meta-analysis, we evaluated the likelihood of recanalization and good neurological outcome (measured with the modified Rankin Score <2 at 90 days) after each device pass. Results Thirteen studies comprising 4197 patients were included. Among cases with failed first pass, 24% of them achieved final complete recanalization and 45% of them achieved final successful recanalization. Independently to the total number of previously failed attempts, the likelihood of achieving successful recanalization was 30% per pass, and the likelihood to achieve complete recanalization was about 20% per pass. The likelihood of good neurological outcome in patients with final successful recanalization decreased after each device pass: 55% after the first pass, 48% after the second pass, 42% after the third pass, 36% after the fourth pass, and 26% for 5 passes or more. Conclusion Each pass is associated with a stable likelihood of recanalization but a decreased likelihood of good neurological outcome.
Findings of the AAPM Ad Hoc committee on magnetic resonance imaging in radiation therapy: Unmet needs, opportunities, and recommendations
McGee, Kiaran P. , Tyagi, Neelam , Bayouth, John E. , Fallone, B. G. , Glide‐Hurst, Carri , Goerner, F, Green, Olga L., Kim, Taeho , Paulson, E.S. , Yanasak, N. E. , Goodwin, James, Jordan, David W. , Hugo, Geoffrey D., Balter, James M. , Kanal, Kalpana M. , Hazle, John D. , Pelc, Norbert J. , Cao, Minsong , Jackson, Edward F. , Dieterich, Sonja , Bernstein, Matt A.

Mayo Clinic

Medical Physics | July 7, 2021 | Volume: 48 | Issue: 8 | Pages: 4523-4531

10.1002/mp.14996 | PMID 34231224 Get It

The past decade has seen the increasing integration of magnetic resonance (MR) imaging into radiation therapy (RT). This growth can be contributed to multiple factors, including hardware and software advances that have allowed the acquisition of high‐resolution volumetric data of RT patients in their treatment position (also known as MR simulation) and the development of methods to image and quantify tissue function and response to therapy. More recently, the advent of MR‐guided radiation therapy (MRgRT) ‐ achieved through the integration of MR imaging systems and linear accelerators ‐ has further accelerated this trend. As MR imaging in RT techniques and technologies, such as MRgRT, gain regulatory approval worldwide, these systems will begin to propagate beyond tertiary care academic medical centers and into more community‐based health systems and hospitals, creating new opportunities to provide advanced treatment options to a broader patient population. Accompanying these opportunities are unique challenges related to their adaptation, adoption, and use including modification of hardware and software to meet the unique and distinct demands of MR imaging in RT, the need for standardization of imaging techniques and protocols, education of the broader RT community (particularly in regards to MR safety) as well as the need to continue and support research, and development in this space. In response to this, an ad hoc committee of the American Association of Physicists in Medicine (AAPM) was formed to identify the unmet needs, roadblocks, and opportunities within this space. The purpose of this document is to report on the major findings and recommendations identified. Importantly, the provided recommendations represent the consensus opinions of the committee’s membership, which were submitted in the committee's report to the AAPM Board of Directors. In addition, AAPM ad hoc committee reports differ from AAPM task group reports in that ad hoc committee reports are neither reviewed nor ultimately approved by the committee’s parent groups, including at the council and executive committee level. Thus, the recommendations given in this summary should not be construed as being endorsed by or official recommendations from the AAPM.
Imaging Quality Control, Methodology Harmonization and Clinical Data Management in Stress Echo 2030
Bartolacelli, Ylenia , Barbieri, Andréa , Antonini‐Canterin, Francesco, Monte, Ines , Trocino, Giuseppe, Barchitta, Agata, Cresti, Alberto , Miceli, Sofia, Petrella, Licia, Benedetto, Frank, Benfari, Giovanni , Zagatina, A , Pálinkás, Eszter Dalma , Toth, S., Wierzbowska‐Drabik, Karina , Djordievic-Dikic, Ana, Pellikka, Patricia A. , Picano, Eugenio, Imaging, on behalf of the Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular, Monte, Ines , Cresti, Alberto , Malagoli, Alessandro , Mantovani, Francesca , Ciampi, Quirino , Zagatina, Angela , Palinkas, Eszter Dalma , Pellikka, Patricia A , Wierzbowska-Drabik, Karina , Barbieri, Andrea , Benfari, Giovanni , Bartolacelli, Ylenia , Pepi, Mauro , Zito, Concetta , Bursi, Francesca , Malagoli, Alessandro , Mantovani, Francesca , Ciampi, Quirino , Pálinkás, Attila , Imaging, on behalf of the Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular

Mayo Clinic

Journal of Clinical Medicine | July 6, 2021 | Volume: 10 | Issue: 14 | Pages: 3020

10.3390/jcm10143020 | PMID 34300186 Get It

Stress echo (SE) 2030 study is an international, prospective, multicenter cohort study that will include >10,000 patients from ≥20 centers from ≥10 countries. It represents the logical and chronological continuation of the SE 2020 study, which developed, validated, and disseminated the “ABCDE protocol” of SE, more suitable than conventional SE to describe the complex vulnerabilities of the contemporary patient within and beyond coronary artery disease. SE2030 was started with a recruitment plan from 2021 to 2025 (and follow-up to 2030) with 12 subprojects (ranging from coronary artery disease to valvular and post-COVID-19 patients). With these features, the study poses particular challenges on quality control assurance, methodological harmonization, and data management. One of the significant upgrades of SE2030 compared to SE2020 was developing and implementing a Research Electronic Data Capture (REDCap)-based infrastructure for interactive and entirely web-based data management to integrate and optimize reproducible clinical research data. The purposes of our paper were: first, to describe the methodology used for quality control of imaging data, and second, to present the informatic infrastructure developed on RedCap platform for data entry, storage, and management in a large-scale multicenter study.
PSC Scientific Community Resource The PSC Scientific Community Resource: An Asset for Multi-Omics Interrogation of Primary Sclerosing Cholangitis
Ali, Ahmad H. , Juran, Brian D., Schlicht, Erik M., Bianchi, Jackie K., McCauley, Bryan M. , Atkinson, Elizabeth J. , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | July 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-629232/v1 Get It

Abstract Background: Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-stage liver disease and/or the development of hepatobiliary neoplasia. Lack of prognostic tools and treatment options for PSC is driven in part by our poor understanding of its pathogenesis, which is thought to be complex, the interaction of genetic variants, environmental influences and biological response throughout the course of disease. The PSC Scientific Community Resource (PSC-SCR) seeks to overcome previous shortcomings by facilitating novel research in PSC with the ultimate goals of individualizing patient care and improving patient outcomes.Methods: PSC patients who receive their health care at Mayo Clinic or a collaborating site are identified by chart review and invited in person or by mail to participate. Non-Mayo patients are offered enrollment if they provide sufficient access to their medical records to evaluate inclusion/exclusion criteria. Controls without liver disease are identified with assistance of the Mayo Clinic Biobank. Participant consent is obtained at the beginning of the recruitment process by mail-in, electronic or face-to-face protocols. Clinical data is extracted from the medical record by qualified physicians and entered in a custom designed database. Participants fill out a custom-designed, comprehensive questionnaire, which collects scientifically relevant demographic and clinical information. Biospecimens are collected using mail-in kitsthar are returned via overnight carrier service and processed by the biospecimen accessioning and processing facility at Mayo Clinic, which coordinates sample transfers and provides required sample preparation services.The resource is currently being utilized to perform omics-scale projects investigating the exposome, metabolome, methylome, immunome and microbiome in PSC. Datasets and residual biospecimens will be shared with researchers proposing scientifically sound PSC-focused research with approval of the appropriate review boards.Discussion:Patient-based studies leveraging the latest technologies for targeted and wide-scale interrogation of multiple omics layers offer promise to accelerate PSC research through discovery of unappreciated aspects of disease pathogenesis. However, the rarity of PSC severely limits such studies. Here we describe our effort to overcome this limitation, the PSC-SCR, a repository of patient biospecimens coupled with clinical and omics data for use by the broader PSC research community.
Understanding the Process and Challenges for Return-to-Work Post-Hematopoietic Cell Transplantation from a Musculoskeletal Perspective: A Narrative Review
Mohammed, Jaleel , Gonzales, Anne , Bakhsh, Hadeel R. , Georgievna, Volkova Alisa, Rai, Jayanti , Kancharla, Bindu, Hashmi, Shahrukh K.

Mayo Clinic

Occupational Therapy International | July 6, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-11

10.1155/2021/5568513 | PMID 34316293 Get It

The current paper seeks to inform healthcare professionals on how adapting various components of return to work (RTW) programs that are already in use by other musculoskeletal rehabilitation settings can help optimize return to work process for patients with or without musculoskeletal manifestations, posthematopoietic cell transplantation. Since there is no universally agreed RTW structure for hematopoietic cell transplant patients, a narrative approach has been taken utilizing evidence from the existing musculoskeletal return to work assessment publications to help draw parallel for the hematopoietic cell transplant patients. Databases were searched including PUBMED, CINHAL, AMED, SCOPUS, and Cochrane using keywords RTW, functional restoration program, hematopoietic cell transplant, bone marrow transplant, stem cell transplant, and musculoskeletal functional assessment. The authors have managed to outline and propose a structured RTW assessment and monitoring program which can aid in getting patients back to employment by utilizing the functional capacity and job evaluation to help hematopoietic cell transplantation patients reintegrate socially. Patients undergoing hematopoietic cell transplant require additional support and a robust assessment system to allow safe RTW. The proposed model of RTW assessment can prove to be beneficial in helping patients return to work safely. Clinical Significance. To acknowledge the individuality in functional limitation is important in determining not only the rehab needs but also the RTW capabilities. The proposed RTW plan not only promotes an individualized approach to patients but also provides a structure for return to work assessments for hematopoietic cell transplantation patients, thus, eliminating the need for guess work by healthcare professionals. In line with the International Classification of Functioning, Disability, and Health (ICF) recommendations, a RTW assessment combined with a job evaluation helps healthcare professionals and stakeholders to understand the unique challenges and strengths of a patient and thereby design an individualized therapy approach.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules
Pokorny, Jenny L. , Mladek, Ann C. , Carlson, Brett L. , He, Lihong , Hu, Zeng, Gampa, Gautham, Kosel, Matthew , Decker, Paul A. , Kitange, Gaspar J. , Schmitt‐Hoffmann, Anne, Bachmann, Felix , Eckel‐Passow, Jeanette E. , McSheehy, Paul M.J., Lane, Heidi A. , Elmquist, William F. , Burgenske, Danielle M. , Bakken, Katrina K. , Schroeder, Mark A. , Giannini, Caterina , Elmquist, William F , Mladek, Ann C , Talele, Surabhi , Decker, Paul A. , Vaubel, Rachael A. , Giannini, Caterina , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | July 6, 2021 | Volume: 24 | Issue: 3 | Pages: 384-395

10.1093/neuonc/noab162 | PMID 34232318 Get It

Abstract Background Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts. Methods Mice bearing intracranial tumors received lisavanbulin +/−RT +/−TMZ and followed for survival. Lisavanbulin concentrations in plasma and brain were determined by liquid chromatography with tandem mass spectrometry, while flow cytometry was used for cell cycle analysis. Results Lisavanbulin monotherapy showed significant benefit (P &lt; .01) in 9 of 14 PDXs tested (median survival extension 9%-84%) and brain-to-plasma ratios of 1.3 and 1.6 at 2- and 6-hours postdose, respectively, validating previous data suggesting significant exposure in the brain. Prolonged lisavanbulin dosing from RT start until moribund was required for maximal benefit (GBM6: median survival lisavanbulin/RT 90 vs. RT alone 69 days, P = .0001; GBM150: lisavanbulin/RT 143 days vs. RT alone 73 days, P = .06). Similar observations were seen with RT/TMZ combinations (GBM39: RT/TMZ/lisavanbulin 502 days vs. RT/TMZ 249 days, P = .0001; GBM26: RT/TMZ/lisavanbulin 172 days vs. RT/TMZ 121 days, P = .04). Immunohistochemical analyses showed a significant increase in phospho-histone H3 with lisavanbulin treatment (P = .01). Conclusions Lisavanbulin demonstrated excellent brain penetration, significant extension of survival alone or in RT or RT/TMZ combinations, and was associated with mitotic arrest. These data provide a strong clinical rationale for testing lisavanbulin in combination with RT or RT/TMZ in GBM patients.
The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
Sharma, Vidit , Miest, Tanner, Chamie, Karim, Boorjian, Stephen A. , Potretzke, Aaron M. , Miest, Tanner S, Matin, Surena F.

Mayo Clinic

Journal of Urology | July 6, 2021 | Volume: 206 | Issue: 4 | Pages: 1072-1072

10.1097/ju.0000000000001929 | PMID 34228501 Get It